{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T19:33:22Z","timestamp":1666467202069},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,29]]},"DOI":"10.18632\/oncotarget.12480","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T18:16:01Z","timestamp":1475691361000},"page":"78577-78590","source":"Crossref","is-referenced-by-count":3,"title":["A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity"],"prefix":"10.18632","volume":"7","author":[{"given":"Yao","family":"Huang","sequence":"first","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Burns","sequence":"additional","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin E","family":"Rich","sequence":"additional","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A","family":"MacNeil","sequence":"additional","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Dandapat","sequence":"additional","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad M.","family":"Soltani","sequence":"additional","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Myhre","sequence":"additional","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian F","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo T","family":"Furcht","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A","family":"Lange","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A","family":"Hurvitz","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance G","family":"Laing","sequence":"additional","affiliation":[{"name":"Celcuity LLC, Minneapolis, MN 55446, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1158\/0008-5472.CAN-04-1945","article-title":"Prognostic relevance of gene amplifications and coamplifications in breast cancer","volume":"64","author":"Mross","year":"2004","journal-title":"Cancer Res"},{"key":"2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Giordano","year":"2010","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Hortobagyi","year":"2009","journal-title":"Oncologist"},{"key":"4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"McGuire","year":"1987","journal-title":"Science"},{"key":"5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ctrv.2013.09.001","article-title":"HER2 testing: current status and future directions","volume":"40","author":"Bartlett","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","article-title":"HER2 status and benefit from adjuvant trastuzumab in breast cancer","volume":"358","author":"Wolmark","year":"2008","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Swain","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"8","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1158\/1078-0432.CCR-14-3012","article-title":"HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive","volume":"21","author":"Moasser","year":"2015","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Hynes","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1158\/0008-5472.CAN-13-1055","article-title":"Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2\/HER3 activation","volume":"74","author":"Diehn","year":"2014","journal-title":"Cancer Res"},{"key":"11","article-title":"Development of a test that measures real-time HER2 signaling activity in live breast cancer cell lines and primary cells","author":"Laing","year":"2016","journal-title":"BMC Cancer"},{"key":"12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/1087057106289334","article-title":"Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array","volume":"11","author":"Abassi","year":"2006","journal-title":"J Biomol Screen"},{"key":"13","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.ddtec.2010.05.001","article-title":"Label-Free Receptor Assays","volume":"7","author":"Fang","year":"2011","journal-title":"Drug Discov Today Technol"},{"key":"14","doi-asserted-by":"crossref","first-page":"e1000279","DOI":"10.1371\/journal.pmed.1000279","article-title":"Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies","volume":"7","author":"Nevanlinna","year":"2010","journal-title":"PLoS Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/1471-2164-7-231","article-title":"Discovery and validation of breast cancer subtypes","volume":"7","author":"Tibshirani","year":"2006","journal-title":"BMC Genomics"},{"key":"16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm.2000","article-title":"Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers","volume":"15","author":"Thorne","year":"2009","journal-title":"Nat Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","article-title":"Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth","volume":"2","author":"Sliwkowski","year":"2002","journal-title":"Cancer Cell"},{"key":"18","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/0008-5472.CAN-03-3106","article-title":"Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects","volume":"64","author":"Brattain","year":"2004","journal-title":"Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.5858\/arpa.2014-0127-OA","article-title":"Evaluation of HER2\/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by FluorescenceHybridization Assay: A 10- Year Experience and Impact of Test Standardization on Concordance Rate","volume":"139","author":"Haley","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/modpathol.2012.93","article-title":"High concordance between HercepTest immunohistochemistry and ERBB2 fluorescencehybridization before and after implementation of American Society of Clinical Oncology\/College of American Pathology 2007 guidelines","volume":"25","author":"Apple","year":"2012","journal-title":"Mod Pathol"},{"key":"21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-13-615","article-title":"Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescencehybridization and immunohistochemistry in a single institution over 12 years: a quality control study","volume":"13","author":"Moch","year":"2013","journal-title":"BMC Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/PDM.0b013e3182360b0a","article-title":"mRNAhybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study","volume":"21","author":"Polo","year":"2012","journal-title":"Diagn Mol Pathol"},{"key":"23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jso.21973","article-title":"The significance of HER-2\/neu receptor positivity and immunophenotype in ductal carcinomawith early invasive disease","volume":"104","author":"Zhang","year":"2011","journal-title":"J Surg Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1073\/pnas.1016140108","article-title":"Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase","volume":"108","author":"Arteaga","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djs501","article-title":"HER3 overexpression and survival in solid tumors: a meta-analysis","volume":"105","author":"Amir","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"26","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-09-3145","article-title":"An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation","volume":"70","author":"Nielsen","year":"2010","journal-title":"Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10549-013-2570-6","article-title":"HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients","volume":"139","author":"Nam","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Mardis","year":"2013","journal-title":"Cancer Discov"},{"key":"29","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/cncr.30102","article-title":"Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies","volume":"122","author":"Waintraub","year":"2016","journal-title":"Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Banerji","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"31","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ejca.2005.11.012","article-title":"Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients","volume":"42","author":"Eppenberger-Castori","year":"2006","journal-title":"Eur J Cancer"},{"key":"32","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1200\/JCO.2000.18.18.3230","article-title":"Activation (tyrosine phosphorylation) of ErbB-2 (HER-2\/neu): a study of incidence and correlation with outcome in breast cancer","volume":"18","author":"DiGiovanna","year":"2000","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.2005.09.055","article-title":"Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients","volume":"23","author":"Thor","year":"2005","journal-title":"J Clin Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/ijc.21492","article-title":"Her-2\/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer","volume":"118","author":"Singer","year":"2006","journal-title":"Int J Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1158\/1078-0432.CCR-12-0452","article-title":"Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping","volume":"18","author":"Becker","year":"2012","journal-title":"Clin Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1634\/theoncologist.2015-0369","article-title":"Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer","volume":"21","author":"Pusztai","year":"2016","journal-title":"Oncologist"},{"key":"37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-61779-833-7_4","article-title":"Bistability in one equation or fewer","volume":"880","author":"Ferrell","year":"2012","journal-title":"Methods Mol Biol"},{"key":"38","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1038\/oncsis.2014.45","article-title":"Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy","volume":"3","author":"Mak","year":"2014","journal-title":"Oncogenesis"},{"key":"39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","article-title":"Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer","volume":"149","author":"Smalley","year":"2012","journal-title":"Cell"},{"key":"40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.celrep.2015.03.037","article-title":"Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains","volume":"11","author":"Kuan","year":"2015","journal-title":"Cell Rep"},{"key":"41","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/annonc\/12.suppl_1.S81","article-title":"Targeting HER2 in other tumor types","volume":"12","author":"Pouillart","year":"2001","journal-title":"Ann Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"43","unstructured":"Stampfer, Yaswen, Taylor-Papadimitriou. Culture of human mammary epithelial cells. Freshney (ed.), Freshney (ed.). Culture of Epithelial Cells."},{"key":"44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nprot.2006.31","article-title":"Reconstruction of human mammary tissues in a mouse model","volume":"1","author":"Kuperwasser","year":"2006","journal-title":"Nat Protoc"},{"key":"45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11626-007-9039-z","article-title":"Serum-free solutions for cryopreservation of cells","volume":"43","author":"Brockbank","year":"2007","journal-title":"Cell Dev Biol Anim"},{"key":"46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0091-679X(01)63016-4","article-title":"Strategies for cell permeabilization and fixation in detecting surface and intracellular antigens","volume":"63","author":"Bolton","year":"2001","journal-title":"Methods Cell Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T14:30:28Z","timestamp":1589293828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":46,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2016,11,29]]}},"alternative-id":["12480","27713176"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12480","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]}}}